Serum magnesium levels may influence development and progression of CKD metabolic disorders: Study

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-07-16T21:00:19+05:30 | Updated On 16 July 2025 9:00 PM IST

A new study published in the journal of Risk Management and Healthcare Policy showed that the frequency of magnesium metabolic abnormalities rises steadily with the severity of chronic kidney disease (CKD), peaking in stage G5.

Chronic kidney disease patients have been shown to have a magnesium metabolic imbalance. However, little is known about the blood magnesium levels of patients with non-dialysis-dependent CKD (NDD-CKD) and how they relate to mineral-skeletal metabolic disorder (CKD-MBD). Thus, this research examined how blood magnesium levels vary over time in patients with non-dialysis-dependent chronic kidney disease and assess how these variations relate to indicators of mineral metabolism (calcium, phosphorus, iPTH, and alkaline phosphatase).

Data from 156 patients with stage 3–5 CKD (G3–G5) who were hospitalized to Handan First Hospital between March 2017 and December 2019 were retrospectively analyzed. The levels of alkaline phosphatase (AKP), intact parathyroid hormone (iPTH), calcium, phosphorus, and magnesium in the serum were measured. Based on their serum magnesium levels, the patients were divided into groups with hypomagnesemia, normal magnesium, and hypermagnesemia. Analysis was done on connections between magnesium levels and phosphorus, AKP, and iPTH levels.

From CKD stages G3 to G5, serum magnesium levels showed an increasing tendency, however this trend was not statistically significant. In the G3, G4, and G5 phases, the frequency of hypermagnesemia was 5.13%, 13.64%, and 30.14%, respectively, whereas the prevalence of hypomagnesemia was 0%, 6.82%, and 15.07%.

While there was no link with blood phosphorus or iPTH levels, there was a strong positive correlation between serum magnesium levels and serum calcium and the calcium-phosphorus product.

Overall, the association between mineral-skeletal metabolic disorder and blood magnesium levels in individuals with chronic kidney disease was investigated in this study. This highlighted the significance of routine magnesium level monitoring and offered basic information regarding the possible involvement of magnesium metabolism in the management of chronic kidney disease, even if it did not explicitly link magnesium levels with clinical outcomes.

Source:

Cao, Y.-P., Zhu, L.-P., Ge, H.-J., Zhang, R.-Q., Chen, R.-J., Yuan, B., & Shi, W.-J. (2025). Impact of serum magnesium levels on mineral-bone metabolism in non-dialysis-dependent chronic kidney disease. Risk Management and Healthcare Policy, 18, 1847–1856. https://doi.org/10.2147/rmhp.s516474

Source : Risk Management and Healthcare Policy

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751